HXP124
Hexima’s lead product, HXP124, is a topical antifungal treatment for onychomycosis or fungal nail infections.
Now Recruiting
Hexima is recruiting volunteers for clinical trials of HXP124. Click below to find out more and to register your interest.
R&D Webinar Recording
Latest NailMail Newsletter
Thank you to those that joined us for our first R&D Webinar held 25 March 2021. We had a great response and an engaged audience who we hope found value in our presentation. A recording of the webinar is now available.
NailMail is Hexima’s regular quarterly newsletter to shareholders, investors and interested parties.
R&D Webinar Recording
Thank you to those that joined us for our first R&D Webinar held 25 March 2021. We had a great response and an engaged audience who we hope found value in our presentation. A recording of the webinar is now available.
Latest NailMail Newsletter
NailMail is Hexima’s regular quarterly newsletter to shareholders, investors and interested parties.
External Links
Take a look at these useful links to learn more about our industry.
